T. Rowe Price Associates
CBIO

T. Rowe Price Associates’s Crescent Biopharma CBIO Stock Holding History

T. Rowe Price Associates’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.58M Sell
303,551
-34,574
-10% -$397K ﹤0.01% 1386
2025
Q4 		$4.01M Sell
338,125
-45,470
-12% -$579K ﹤0.01% 1475
2025
Q3 		$4.56M Buy
+383,595
New +$5.09M ﹤0.01% 1420
2019
Q3 		– Sell
-30,444
Closed -$36.3M – 2532
2019
Q2 		$36.3M Sell
30,444
-3,798
-11% -$4.54M 0.01% 988
2019
Q1 		$42.7M Sell
34,242
-384
-1% -$440K 0.01% 933
2018
Q4 		$32.8M Buy
34,626
+190
+0.6% +$229K 0.01% 975
2018
Q3 		$49.6M Sell
34,436
-39
-0.1% -$59K 0.01% 915
2018
Q2 		$55.6M Buy
34,475
+5,767
+20% +$9.92M 0.01% 853
2018
Q1 		$46.6M Buy
28,708
+16,058
+127% +$33.4M 0.01% 903
2017
Q4 		$21.2M Buy
12,650
+1,661
+15% +$2.2M ﹤0.01% 1168
2017
Q3 		$15.4M Sell
10,989
-2,639
-19% -$3.1M ﹤0.01% 1261
2017
Q2 		$15.2M Buy
+13,628
New +$11.3M ﹤0.01% 1240
2015
Q1 		– Sell
-913
Closed -$658K – 2555
2014
Q4 		$658K Buy
+913
New +$715K ﹤0.01% 1845

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's CBIO Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Crescent Biopharma (CBIO) stake by 10% in Q1 2026, selling an estimated $397K and leaving 303,551 shares worth $5.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1386.

T. Rowe Price Associates first reported a position in CBIO in Q4 2014 and has held it in 13 quarters since. The position peaked at $55.6M in Q2 2018. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • T. Rowe Price Associates held 303,551 shares of Crescent Biopharma worth $5.58M as of Q1 2026.
  • T. Rowe Price Associates sold 34,574 Crescent Biopharma shares in Q1 2026, an estimated $397K.
  • Crescent Biopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1386 holding.
  • T. Rowe Price Associates first reported a position in Crescent Biopharma in Q4 2014 and has held it in 13 quarters since.
  • T. Rowe Price Associates's Crescent Biopharma position peaked at $55.6M in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.